If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Patricia Carr Biography and Net Worth

SVP of Jazz Pharmaceuticals

Patricia Carr serves as Vice President, Finance and Principal Accounting Officer of the Company. Prior to that, from September 2011 to July 2012, she served as Vice President, Finance of Alkermes plc, a global biopharmaceutical company. From June 2002 to September 2011, she served in a number of roles in Elan Corporation, a neuroscience-based biotechnology company, most recently as Vice President, Finance.

What is Patricia Carr's net worth?: The estimated net worth of Patricia Carr is at least $878,217.06 as of March 15th, 2023. Ms. Carr owns 6,286 shares of Jazz Pharmaceuticals stock worth more than $878,217 as of March 21st. This net worth approximation does not reflect any other assets that Ms. Carr may own. Learn More about Patricia Carr's net worth.
How do I contact Patricia Carr?: The corporate mailing address for Ms. Carr and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected] Learn More on Patricia Carr's contact information.
Has Patricia Carr been buying or selling shares of Jazz Pharmaceuticals?: In the last ninety days, Patricia Carr has sold $297,876.54 of Jazz Pharmaceuticals stock. Most recently, Patricia Carr sold 1,023 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $133.22, for a transaction totalling $136,284.06. Following the completion of the sale, the chief accounting officer now directly owns 6,286 shares of the company's stock, valued at $837,420.92. Learn More on Patricia Carr's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Bruce Cozadd (CEO), Patrick Enright (Director), Peter Gray (Director), Finbar Larkin (SVP), Seamus Mulligan (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), and Christopher Tovey (COO). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 40 times. They sold a total of 162,354 shares worth more than $24,122,859.21. The most recent insider tranaction occured on March, 15th when CAO Patricia Carr sold 1,023 shares worth more than $136,284.06. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 3/15/2023.

Patricia Carr Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2023	Sell	1,023	$133.22	$136,284.06	6,286
3/5/2023	Sell	1,148	$140.76	$161,592.48	7,309
12/5/2022	Sell	63	$152.06	$9,579.78	5,934
8/15/2022	Sell	2,142	$160.06	$342,848.52	5,934
5/11/2022	Sell	722	$147.51	$106,502.22	6,234
5/9/2022	Sell	1,067	$148.94	$158,918.98	7,229
8/6/2021	Sell	157	$147.96	$23,229.72	6,035
12/4/2020	Sell	62	$152.55	$9,458.10
8/12/2020	Sell	142	$123.80	$17,579.60	6,200
8/7/2020	Sell	158	$125.87	$19,887.46	6,342
6/5/2020	Sell	138	$124.00	$17,112.00
3/12/2020	Sell	600	$102.17	$61,302.00	6,500
3/9/2020	Sell	568	$111.45	$63,303.60	7,668
3/6/2020	Sell	232	$119.17	$27,647.44	7,668
3/3/2020	Sell	247	$119.75	$29,578.25	8,153
12/5/2019	Sell	1,749	$148.93	$260,478.57

Patricia Carr Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $139.71

$138.62

$140.78

50 Day Range

MA: $148.20

$133.98

$157.77

2 Week Range

Now: $139.71

$125.36

$169.98

Volume

393,854 shs

Average Volume

542,094 shs

Market Capitalization

$8.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

The Safest Option in Trades!

From Tradewins | Ad

Click here now!